CRNX
Crinetics Pharmaceuticals Inc
85.00$
+0.0%
vs. previous close
Closing price · As of: Sep 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.0% | +54.0% | -4.4% | +0.2% | +53.0% | -5.1% | -5.3% | -7.3% | -5.1% | +23.4% | -5.7% | |
| – | -0.3% | +59.8% | -4.6% | +0.3% | +56.7% | -6.1% | -5.7% | -7.9% | -6.5% | +26.1% | -5.9% | |
| – | -61.6% | +621.2% | -23.7% | +5.0% | -16.6% | -64.3% | -43.2% | +106.4% | -8.4% | +12.6% | -51.5% | |
| – | +0.7% | +61.3% | -4.2% | 0.0% | +57.0% | -5.9% | -6.1% | -8.7% | -5.9% | +25.6% | -6.6% | |
| – | -19.7% | +1.0% | -46.0% | +37.8% | +20.5% | -13.6% | – | – | – | +860.0% | +110.4% | |
| – | – | – | – | – | – | – | – | – | – | +51.5% | +13.8% | |
| – | +2.6% | +7.2% | +1.5% | -0.4% | +5.2% | -2.2% | +10.0% | +4.9% | +15.8% | -15.9% | +7.7% | |
| – | +8.6% | +17.8% | +5.0% | -1.5% | +11.4% | -4.0% | +19.3% | +8.4% | +14.7% | -16.4% | +12.4% | |
| – | +4.6% | +38.8% | +28.5% | -0.4% | -3.5% | -3.8% | -4.0% | -2.6% | +0.7% | +0.7% | +0.7% | |
| – | +12.1% | +64.3% | -17.5% | -44.3% | +18.5% | +68.2% | +15.1% | -46.1% | +270.1% | -43.0% | +2.9% | |
| – | -1.6% | +62.3% | -5.0% | +0.3% | +59.0% | -5.3% | -6.6% | -8.5% | -7.5% | +29.1% | -6.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +18.2% | +7.7% | +9.3% | +1.4% | +14.2% | +1.8% | +0.7% | +0.5% | -0.2% | +10.7% | +1.4% |
Data as of: September 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.